Aflibercept efficacy according to sidedness, RAS and BRAF mutations. Findings from the VELOUR trial in second line therapy of advanced colorectal cancer patients
Titel:
Aflibercept efficacy according to sidedness, RAS and BRAF mutations. Findings from the VELOUR trial in second line therapy of advanced colorectal cancer patients
Auteur:
Maiello, E. Pomella, V. Wirapati, P. Di Bartolomeo, M. Zampino, M.G. Leone, F. Latiano, T.P. Pietrantonio, F. Ravenda, P.S. Marino, D. Tejpar, S.